Biostar Pharmaceuticals, a Xianyang-based manufacturer of over-the-counter Hepatitis B medicine, has hired Zack Zibing Pan as its new chief financial officer (CFO). This appointment followed resignation of Deyin (Bill) Chen, for personal reasons. Prior to this appointment, Pan served as an independent member of the board and the chairman of the audit committee of the board of directors of the company and, consequently, had to step down as a board and audit committee member in order to be engaged as the company’s new CFO.
Pan has over 10 years of accounting and finance experience. Previously, he was CFO of China Education Alliance, where he was appointed in August 2009. Prior to that, Pan was an audit manager with Eide Bailly CPAs & Business Advisors, where he has been employed since September 2005.
From September 1998 to September 2005, Pan was a statistical analyst and economist with the State of Oklahoma. Pan graduated with a MBA from the University of Central Oklahoma in 1999. He holds a BA degree from Anhui University, China (1988). He is a certified public accountant (CPA), certified by the Oklahoma State Board of Accountancy, and member of American Institute of Certified Public Accountant and Oklahoma Society of Certified Public Accountants.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.